Atle Fund Management AB Takes $1.84 Million Position in Celcuity, Inc. $CELC

Atle Fund Management AB bought a new position in shares of Celcuity, Inc. (NASDAQ:CELC) in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 37,157 shares of the company’s stock, valued at approximately $1,836,000. Atle Fund Management AB owned about 0.09% of Celcuity as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of CELC. BNP Paribas Financial Markets grew its holdings in Celcuity by 78.9% during the 2nd quarter. BNP Paribas Financial Markets now owns 2,647 shares of the company’s stock worth $35,000 after acquiring an additional 1,167 shares during the period. Tower Research Capital LLC TRC boosted its position in shares of Celcuity by 211.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,549 shares of the company’s stock valued at $74,000 after purchasing an additional 3,766 shares in the last quarter. Avanza Fonder AB bought a new stake in shares of Celcuity during the 3rd quarter valued at about $79,000. Versant Capital Management Inc grew its stake in Celcuity by 611.2% during the third quarter. Versant Capital Management Inc now owns 1,593 shares of the company’s stock worth $79,000 after purchasing an additional 1,369 shares during the period. Finally, AlphaQuest LLC increased its holdings in Celcuity by 176.3% in the second quarter. AlphaQuest LLC now owns 7,087 shares of the company’s stock worth $95,000 after purchasing an additional 4,522 shares in the last quarter. Institutional investors own 63.33% of the company’s stock.

Insider Activity at Celcuity

In related news, Director Richard E. Buller sold 3,900 shares of the company’s stock in a transaction on Thursday, November 20th. The stock was sold at an average price of $96.73, for a total transaction of $377,247.00. Following the completion of the sale, the director owned 7,260 shares in the company, valued at approximately $702,259.80. This represents a 34.95% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director David Dalvey sold 20,000 shares of the stock in a transaction on Tuesday, January 27th. The shares were sold at an average price of $120.03, for a total value of $2,400,600.00. Following the completion of the sale, the director directly owned 90,000 shares of the company’s stock, valued at $10,802,700. The trade was a 18.18% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 26,900 shares of company stock worth $3,094,917. 15.77% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of research firms have issued reports on CELC. Weiss Ratings restated a “sell (d-)” rating on shares of Celcuity in a report on Wednesday, January 21st. Wall Street Zen lowered shares of Celcuity from a “hold” rating to a “sell” rating in a research note on Sunday, October 26th. Jefferies Financial Group lifted their price target on shares of Celcuity from $108.00 to $134.00 and gave the company a “buy” rating in a research note on Tuesday, December 2nd. Wolfe Research assumed coverage on shares of Celcuity in a research report on Tuesday, November 18th. They set an “outperform” rating and a $110.00 price objective on the stock. Finally, Wells Fargo & Company began coverage on Celcuity in a research report on Friday, December 12th. They issued an “overweight” rating and a $126.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Celcuity presently has an average rating of “Moderate Buy” and a consensus target price of $105.25.

Celcuity Trading Down 2.4%

NASDAQ:CELC opened at $109.42 on Friday. The company has a debt-to-equity ratio of 2.74, a current ratio of 12.26 and a quick ratio of 12.26. Celcuity, Inc. has a one year low of $7.57 and a one year high of $120.32. The company has a market cap of $5.06 billion, a PE ratio of -29.81 and a beta of 0.25. The firm has a 50-day moving average of $104.24 and a 200-day moving average of $72.14.

Celcuity (NASDAQ:CELC) last announced its quarterly earnings results on Wednesday, November 12th. The company reported ($0.92) earnings per share for the quarter, beating the consensus estimate of ($1.05) by $0.13. As a group, equities research analysts expect that Celcuity, Inc. will post -2.62 EPS for the current fiscal year.

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.